Entries by WuXi AppTec

Improved cyclization conditions to prepare 6-substituted pyrazolo[1,5-a]pyridines and pyrazolo[1,5-a]pyrazines using catalytic Ag(I) and Au(III) salts. John F. Braganza, et. al. Tetrahedron Letters, 2015, 56(42), pp. 5757-5760.   Development of a Scalable Synthesis of 4-Aminopyrimidin-5-ol, a Versatile Intermediate. Phuong T. Le, et. al. Organic Process Research and Development, 2015, 19(6), pp.639-645.

  Medicinal Chemistry   Novel recurrent mutations in ethanolamine kinase 1 (ETNK1) gene in systemic mastocytosis with eosinophilia and chronic myelomonocytic leukemia. T L Lasho et. al. Blood Cancer Journal 2015 5(e275).   A new family of choline kinase inhibitors with antiproliferative and antitumor activity derived from natural products. A. Estvez-Braun, et. al.,Clinical Translational Oncology. 2015, […]

BAYpress November 2015

WuXi News Gilead Sciences and WuXi Partner for a Dedicated Analytical and Stability Testing Facility Read full article here WuXi and Lilly Collaborate to Develop Novel Therapeutics in China Read full article here WuXi Receives 2015 Asian CRO Company of the Year Award from Frost & Sullivan Read full article here Congratulations to Novira Therapeutics for […]

ILpress November 2015

UPCOMING: WuXi Representatives Visit Israel for EFMC-ASMC’15     Members of WuXi’s small molecule drug discovery platform (International Discovery Service Unit – IDSU) will be attending the EFMC International Symposium on Advances in Synthetic and Medicinal Chemistry from November 15-18 to meet with Israeli clients and colleagues. WuXi brings world class capability and capacity through […]

MApress October 2015

WuXi News WuXi Receives 2015 Open-Access R&D Technology Leadership Award from Frost & Sullivan Read full article here WuXi Receives 2015 Asian CRO Company of the Year Award from Frost & Sullivan Read full article here WuXi Boston Welcomes Valdas Jurkauskas to Join the STA Team: An Interview with Valdas Jurkauskas, Executive Director, Technical Operations, […]

BAYpress September 2015

WuXi News WuXi NextCODE in Bloomberg on Ending a 30-year Diagnostic Odyssey in 3 Weeks Read full article here WuXi NextCODE Featured in Nature as the Innovative Engine of Population-scale Precision Medicine at Genomics England and Beyond  Read full article here WuXi Receives 2015 Open-Access R&D Technology Leadership Award from Frost & Sullivan Read full […]

SDpress October 2015

  WuXi News Dr. Peter Schultz, CEO of The Scripps Research Institute, Visits WuXi Headquarters in Shanghai   Read full article here WuXi Receives 2015 Open-Access R&D Technology Leadership Award from Frost & Sullivan Read full article here WuXi Receives 2015 Asian CRO Company of the Year Award from Frost & Sullivan Read full article here […]

IL Press September 2015

Meet WuXi’s Israel Partner: An Interview with Ran Nussbaum, Co-Founder and Managing Partner of Pontifax   Read full interview here Wuxi City Mayor Visits WuXi’s Israel Office The Wuxi government delegation visited Israel last week exploring ways to promote economic transformation for Wuxi city through developing advanced technologies and cultivating potential collaborations between Israel and Wuxi companies. Dana Yarden of WuXi’s Israel Office had […]

Congratulations to Novira Therapeutics

  We are pleased to share with you that our partner and WuXi Venture Fund portfolio company Novira Therapeutics has agreed to be acquired by Johnson & Johnson.  Novira’s lead compound, NVR 3-778, is a small-molecule, direct-acting antiviral for oral administration in patients with hepatitis B virus (HBV).  The compound inhibits the HBV core or […]

IDSUpress August 2015 Newsletter

   Welcome Message from Steve Yang Welcome to the inaugural IDSU newsletter! As the new head of the International Discovery Services Unit (IDSU), I am proud to introduce our quarterly newsletter, bringing you the latest in medicinal chemistry and small molecule news, research, and events. For over a decade, WuXi AppTec has built an open […]